James Foran
0000-0003-1673-1708
16 papers found
Refreshing results…
TP53 variant allele frequency and therapy‐related setting independently predict survival in myelodysplastic syndromes with del(5q)
Venetoclax plus hypomethylating agents in DDX41‐mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients
Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG‐ACRIN analysis
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases
Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real‐world experience
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
Nonimmunoglobulin Crystal-Storing Histiocytosis (CSH): Case Report and Literature Review
Venetoclax plus hypomethylating agent in blast‐phase myeloproliferative neoplasm: preliminary experience with 12 patients
Biphenotypic Acute Leukemia versus Myeloid Antigen-Positive ALL: Clinical Relevance of WHO Criteria for Mixed Phenotype Acute Leukemia
Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes
Missing publications? Search for publications with a matching author name.